Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
BILLERICA, Massachusetts --- June 20, 2007 --- Millipore Corporation today announced the release of new data concerning its ReNcell neural stem cell lines. The research was conducted by the Department of Physiology at University College London and ReNeuron Group plc, whose ReNcell distribution agreement with Millipore was announced in 2006. The data will be presented by Dr. Vi Chu, research & development scientist for Millipore’s Bioprocess Division, in a technology talk at the ISSCR meeting in Cairns, Australia on June 20, 2007.
The data conclude that the ReNcell lines, ReNcell VM and ReNcell CX, will continuously expand in monolayer culture. Both cell lines have the ability to differentiate into neurons, astrocytes and oligodendrocytes, and the researchers were able to differentiation the ReNcell VM line into electrophysiologically active dopaminergic neurons. The study was published in the May edition of BMC Neuroscience and may be read in its entirety at: www.biomedcentral.com/1471-2202/8/36/abstract.
The ReNcell neural stem cell lines are immortalized human neural progenitor cells that have the ability to readily differentiate into neural cell types and will replicate indefinitely. ReNcell immortalized cells display the same marker patterns as normal cells and are able to grow and remain stable after culturing. These cells are important tools for the discovery of new therapies targeting diseases of the central nervous system.
Millipore’s Bioscience Division provides innovative tools, services and biological reagents that drive advancements in biomedical and academic research as well as support the discovery and development of new pharmaceuticals. The product portfolio has been further enhanced with the 2006 addition of Chemicon, Upstate and Linco product lines, allowing Millipore to provide the most complete offering of life science tools on the market. Our customers work in leading research laboratories across a variety of industries throughout the world. Millipore improves their laboratory productivity and efficiency through optimized workflows. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.
Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps enables pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows. Its products and enabling technologies that are used in the laboratory are essential for the research and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide. For additional information on Millipore Corporation, please visit its website at: www.millipore.com.
About ReNeuron Group plc
ReNeuron Group plc is a leading player in the stem cell field, using human somatic stem cells to develop leading edge therapies for neurodegenerative and other diseases. The Group has also leveraged their stem cell technologies into non-therapeutic areas such as drug discovery. ReNeuron was founded in 1997 to commercialize technology discovered by its founding scientists working at the Institute of Psychiatry, Kings College London. ReNeuron currently employs around 30 staff, including 15PhDs, with many years combined experience in stem cell research and development. ReNeuron operates form state-of-the-art laboratories in Guildford, Surrey, UK, which are fitted out to meet the stringent requirements of the regulatory authorities for cell therapy products. For additional information on ReNeuron, please visit its website at: www.reneuron.com.
Millipore is a registered trademark of Millipore Corporation. ReNcell is a registered trademark of ReNeuron Group plc.
Posted: June 2007